Insights on adjuvant endocrine therpay for premenopausal and postmenopausal breast cancer

Susanne Briest, Antonio C. Wolff

Research output: Contribution to journalReview article

Abstract

In 2005, cancer accounted for 13% of all deaths worldwide. Breast cancer is the number-one cause of cancer-related death among women in the USA, affecting 178,480 of them in 2007. As 75% of tumors in postmenopausal women and half in premenopausal women express estrogen receptor, endocrine therapy plays a significant role as a systemic treatment. Robust datasets have demonstrated the impact of tamoxifen in reducing breast cancer recurrence and mortality, regardless of the age of the patient. Other estrogen-deprivation strategies, such as aromatase inhibitors in postmenopausal women and luteinizing hormone-releasing hormone agonists in premenopausal women, are being increasingly used for estrogen receptor-positive breast cancer. This review discusses basic principles regarding endocrine therapy, the need for accurate estrogen receptor testing and the role of menopause in therapy selection.

Original languageEnglish (US)
Pages (from-to)1243-1253
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume7
Issue number9
DOIs
StatePublished - Sep 1 2007

Keywords

  • Adjuvant treatment
  • Aromatase inhibitors
  • Breast cancer
  • Endocrine therapy
  • Estrogen receptor
  • Hormonal treatment
  • Luteinizing hormone-releasing hormone agonist
  • Postmenopausal
  • Premenopausal

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Insights on adjuvant endocrine therpay for premenopausal and postmenopausal breast cancer'. Together they form a unique fingerprint.

  • Cite this